Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana.
Nowadays, there are many tools for cancer diagnosis, from imaging techniques to biopsies. In traditional blood tests, liquid biopsy bursts onto the scene as an explosion of possibilities driven by molecular techniques for the detection and sequencing of proteins or genetic material. But specialists are cautious because they know that in liquid biopsies not everything is detected. At the ENA 2022 session “The role of ctDNA in clinical trials,” Marie Morfouace, a translational researcher at the EORTC, presented “ctDNA in clinical trial practice today,” where she described the balance of the possibilities of the liquid biopsy when confronting it with the results in patients offered by the studies published to date.
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza.
At the Saturday, Oct. 22 session, ‘Basic Science: Correlates of protection, immune response and the host-microbe interaction,’ of the IDWeek 2022 infectious disease conference, moderator Luiz Bermudez, professor at Oregon State University, introduced the latest advances to prevent infections with Treponema pallidum during neurosyphilis (NS), Staphylococcus aureus and osteomyelitis, and Mycobacterium tuberculosis during influenza.
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
A group of scientists from The Ohio State University (OSU) in collaboration with the University of Chicago has found that targeting the enzyme NSUN2 could be used against a wide range of viruses. Its deficiency could stop infection by inhibiting gene expression and viral replication.
Three years after WHO declared the COVID-19 pandemic, some patients are still reporting symptoms from long-ago infections. And the scientific community is studying the reasons for the post-acute sequelae of SARS-CoV-2 (PASC). Until now, the studies provided varied reasons related to persistent COVID or PASC, such as acute SARS-CoV-2 injury in different organs, or reservoirs of the virus in certain tissues, as it happens with other pathogens like HIV. At the IDWeek 2022 infectious disease conference held this week in Washington, D.C., Eric Daar, chief of the Division of HIV Medicine at the Lundquist Institute at Harbor-UCLA Medical Center, moderated the session, 'COVID-19: Post-acute sequelae', where talks offered new results on the symptoms of people who have suffered prolonged COVID during the pandemic.
